Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 4:17:2227-2236.
doi: 10.2147/IDR.S460148. eCollection 2024.

The Trend of Antibiotic Consumption After the COVID-19 Pandemic: Approach to Future Outbreaks

Salah H Elsafi  1 , Saleh H Almutairi  2 , Mujahid A Alsulaimani  3 , Salma AlBahrani  4 , Thekra N Al-Maqati  1 , Wafa K Alanazi  2 , Mohammed N Alanazi  2 , Abdullah A Alamri  2 , Majed Hamoud Alkhathami  5 , Rakkad A Alshammari  5 , Naif F Alharbi  5 , Yaser A Al Naam  1
Affiliations

The Trend of Antibiotic Consumption After the COVID-19 Pandemic: Approach to Future Outbreaks

Salah H Elsafi et al. Infect Drug Resist. .

Abstract

Background: Earlier reports suggested high rates of antibiotic utilization among COVID-19 patients despite the lack of direct evidence of their activity against viral pathogens. Different trends in antibiotic consumption during 2020 compared to 2019 have been reported.

Purpose: The objective of this study is to assess the impact of COVID-19 pandemic on antibiotic consumption in the presence of active Antibiotic Stewardship Program.

Methods: This study represented a five years assessment of the consumption of the commonly prescribed antibiotics measured as DDDs/100-Bed Days. We analyzed the data by using nonparametric Friedman and Friedman tests to compare the antibiotic consumption before and during the three subsequent waves of COVID-19.

Results: Antibiotic consumption through the DDDs/100-BD has shown reduction in the median of antibiotics consumption of most antibiotics during the period of COVID-19 as compared to the pre-COVID-19 period, which was significant for meropenem and ciprofloxacin, except colomycin that slightly increased. Significant reduction in the consumption of imipenem and meropenem during the second and third waves as compared to the pre-COVID period. Throughout the years, significant reductions were observed between 2018 and 2019 (p=<.001), 2018 and 2020 (p=0.008), and 2018 and 2022 (p=0.002).

Conclusion: The reduction in antibiotic consumption is attributed to the strong influence if the ASP and the reluctance of people to visit hospitals during the COVID-19 pandemic. Other related COVID-19 precautions such as physical distance, good hand hygiene, facemasks, that resulted in the prevention of secondary bacterial infections have contributed to the reduction in antibiotic utilization during the pandemic.

Keywords: ASP; COVID-19; DDD; Saudi Arabia; antibiotic consumption; antimicrobial stewardship; defined daily doses.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Antibiotic consumption as a median DDDs/100-BD during 2018–2022.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stevens RW, Jensen K, O’Horo JC, Shah A. Antimicrobial prescribing practices at a tertiary-care center in patients diagnosed with COVID-19 across the continuum of care. Infect Control Hosp Epidemiol. 2021;42(1):89–92. doi:10.1017/ice.2020.370 - DOI - PMC - PubMed
    1. Zhu N, Aylin P, Rawson T, Gilchrist M, Majeed A, Holmes A. Investigating the impact of COVID-19 on primary care antibiotic prescribing in North West London across two epidemic waves. Clin Microbiol Infect. 2021;27(5):762–768. doi:10.1016/j.cmi.2021.02.007 - DOI - PMC - PubMed
    1. Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clinl Infect Dis. 2021;72(10):e533–e541. - PMC - PubMed
    1. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520–531. doi:10.1016/j.cmi.2020.12.018 - DOI - PMC - PubMed
    1. Alshaikh FS, Godman B, Sindi ON, Seaton RA, Kurdi A. Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: a systematic review and meta-analysis. PLoS One. 2022;17(8):e0272375. doi:10.1371/journal.pone.0272375 - DOI - PMC - PubMed